This inventor holds 55 USPTO granted patents and 3 published patent applications, plus 6 CIPO patents and 26 EPO patents, primarily in NIK Inhibitors (CPC class A61K). Top assignees: Genentech, Inc., Curis, Inc., F. Hoffmann-La Roche Ag. Active years: 2003-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Aylesbury, GB (2003 - 2004)
- Aylesbury Bucks, GB (2005)
- Hartford, GB (2006)
- Hertford, GB (2007 - 2014)
- Hunsdon Ware, GB (2014)
- Harlow, GB (2010 - 2017)
- Harlow Essex, GB (2013 - 2017)
- Essex, GB (2018 - 2020)
Company Filing History:
22 out of 3,299 
13 out of 141 
8 out of 181 
Years Active: 2003-2020
Areas of Expertise:
Title: Spotlight on Inventor Stephen Colin Price
Introduction:
Stephen Colin Price, a prolific inventor based in Essex, GB, has made significant contributions in the field of pharmaceutical agents. With an impressive portfolio of 55 patents, Price's innovative work has focused on developing inhibitors for NF-κB-inducing kinase (NIK) to address a range of diseases including cancer, inflammatory disorders, metabolic disorders, and autoimmune disorders.
Latest Patents:
1. Pyrazolopyrimidine derivatives as NIK inhibitors: Price's groundbreaking invention in the realm of pharmaceutical agents presents compounds that target NIK, offering potential therapeutic solutions for various health conditions.
2. Thienopyrimidine derivatives as NIK inhibitors: Another noteworthy patent by Price, which underscores his commitment to advancing treatments for cancer, inflammatory disorders, metabolic disorders, and autoimmune disorders.
Career Highlights:
Price has honed his expertise through his tenure at esteemed companies such as Genentech, Inc., and Curis, Inc. His professional journey is marked by a dedication to pioneering novel pharmaceutical agents and pushing the boundaries of medical science.
Collaborations:
In his innovative endeavors, Price has collaborated with esteemed colleagues such as Robert Andrew Heald and Edward Andrew Boyd. These partnerships have enriched the research landscape and propelled the development of cutting-edge solutions in healthcare.
Conclusion:
Inventor Stephen Colin Price stands as a trailblazer in the realm of pharmaceutical innovation, with a remarkable track record of patents aimed at revolutionizing therapeutic approaches. His contributions underscore a relentless pursuit of advancing treatments for a diverse range of medical conditions, solidifying his position as a visionary in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile